Novo Nordisk A/S
CSE:NOVO B
Novo Nordisk A/S
CSE:NOVO B
Price:
850.6 DKK
-2.58%
Market Closed
Updated:
May 5, 2024
Novo Nordisk A/S
Cost of Revenue
|
Novo Nordisk A/S
Cost of Revenue Peer Comparison
Comparables:
HLUN A
ALK B
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Novo Nordisk A/S
CSE:NOVO B
|
Cost of Revenue
-kr35.8B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-10%
|
|
|
H Lundbeck A/S
CSE:HLUN A
|
Cost of Revenue
-kr4.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ALK-Abello A/S
CSE:ALK B
|
Cost of Revenue
-kr1.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
See Also
What is Novo Nordisk A/S's Cost of Revenue?
Cost of Revenue
-35.8B
DKK
-35.8B
DKK
Based on the financial report for Dec 31, 2023, Novo Nordisk A/S's Cost of Revenue amounts to -35.8B DKK.
What is Novo Nordisk A/S's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-10%
-10%
Over the last year, the Cost of Revenue growth was -26%. The average annual Cost of Revenue growth rates for Novo Nordisk A/S have been -20% over the past three years , -15% over the past five years , and -10% over the past ten years .
You don't have any saved screeners yet
